Gene and Cell Therapy Development: Biospecimen Solutions

Featured Image Credit: https://www.genome.gov/ – Gene therapy vector (Public Domain – NIH NHGRI)

The Gene and Cell Therapy Revolution and Its Biospecimen Demands

Gene and cell therapies are changing how we treat inherited diseases, cancer, and immune disorders across the United States. In vivo gene therapy programs increasingly use viral vectors to deliver treatment directly to target tissues. Ex vivo approaches instead engineer a patient’s or donor’s own cells to provide lasting therapeutic effects. Both approaches share one requirement: careful, stage-appropriate biospecimen sourcing that supports discovery, process development, testing, and long-term safety monitoring.

Biospecimen choices shape how well researchers can interpret preclinical studies, compare manufacturing runs, and build a strong clinical translation package. That’s true from viral vector immune responses all the way to the quality of starting cell material. Programs commonly combine immune monitoring, genomic testing, and long-term safety follow-up — making a multi-sample biospecimen strategy essential, not optional.

Key sample types include leukapheresis-derived starting material such as Human Leukopak for cell therapy process development and clinical manufacturing. Cellular immune samples such as Human PBMCs support immune profiling and function tests, while Human CD3 T Cells support focused expansion and engineering work. Monitoring samples such as Human Whole Blood and Human Plasma track safety, immune response, and drug activity. Paired with detailed genomic annotation, these samples support confident decisions at every stage of therapy development.

Viral Vector Platforms: AAV, Lentivirus, and Immunogenicity Considerations

Viral vectors remain central to both in vivo and ex vivo gene delivery. Adeno-associated virus (AAV) is widely used for in vivo gene therapy because it can target specific tissues, has a strong clinical track record, and can support lasting gene expression in tissues that don’t divide. Lentiviral vectors (LVV) are commonly used to engineer blood stem cells and T cells outside the body, since they integrate stably into the genome and can be manufactured at scale.

Choosing the right vector depends on payload size limits, the biology of the target tissue, how long the effect needs to last, and immune risks. AAV programs often deal with pre-existing antibodies against the vector’s protein shell, complement activation risk, innate immune sensing, and immune responses that can limit dosing or re-dosing. Lentiviral vectors bring their own concerns, including testing for replication-competent virus, checking for unwanted mutations from DNA integration, and setting vector copy number targets that balance potency and safety.

Immune response studies commonly use Human Plasma to measure pre-existing and treatment-related anti-vector antibodies, complement activation markers, and cytokine changes over time. Sampling plasma repeatedly over time can tell baseline immunity apart from a response caused by the therapy. It can also inform who to exclude from a trial, what precautions to take, and how to interpret whether the therapy worked. Cellular immune profiling using PBMCs can add to this by mapping T cell responses against the vector’s shell and innate activation patterns that affect how long the treatment lasts.

Immune response patterns can shift with prior infections, age, and immune history. That’s why thorough genomic annotation and clinical context are essential for interpreting immune results across different patient groups and their history of exposure to viral proteins.

Ex Vivo Cell Therapy Manufacturing: Starting Materials and Process Development

Ex vivo programs — including CAR-T, TCR-engineered T cells, CAR-NK, and blood stem cell gene therapy — start with high-quality cellular starting material. Leukapheresis products provide concentrated immune cells that support enriching target cell types, activating them, modifying their genes, and expanding them under controlled conditions. The makeup and starting activation level of this input material can strongly affect several outcomes: how well the cells take up the therapy, how fast they grow, what cell types result, and how well potency tests perform.

Human Leukopak is commonly used during discovery and process development, where flexibility, fast iteration, and a broad range of donors support optimization. These materials can be used in engineering workflows that include activation, viral gene transfer, electroporation, gene editing, expansion, and freezing for storage.

For focused studies, Human CD3 T Cells support research into T cell-specific activation and expansion, helping optimize CD4/CD8 ratios, memory cell types, exhaustion markers, and cytokine release. This data can directly shape product design decisions, like choosing naïve or central memory-enriched starting cells and picking the right culture supplements to preserve the desired cell type.

At the same time, Human PBMCs remain essential for developing assays and planning immune monitoring strategies. These include ELISpot, intracellular cytokine staining, and detailed flow cytometry panels that will later be used on clinical samples to track immune correlates of response.

Gene Editing Modalities and Analytical Control Strategies

Gene and cell therapy programs increasingly use genome editing tools like CRISPR/Cas systems, TALENs, base editing, and prime editing. Each editing method comes with its own testing and biospecimen needs: how well it edits the intended target, whether it edits unintended targets, whether it causes chromosome rearrangements, and how well it performs functionally. Editing workflows also need careful control of innate immune activation, since DNA damage responses can affect cell survival and behavior.

Standard testing typically includes measuring editing rates, vector copy number, leftover reagents, and product purity and identity. For viral vector-based engineering, tests may measure how well the cells took up the vector and how many copies integrated. For non-viral editing, tests instead focus on how precisely and how often edits happened, and whether chromosomes rearranged. Potency tests measure how well the edited cells kill target cells, produce cytokines, multiply, and engage their target under set conditions.

Long-term safety monitoring is central to gene therapy, especially for methods that integrate into the genome or edit it directly, where unwanted mutations or unchecked cell growth must be ruled out. Human Whole Blood supports the genomic and molecular monitoring used in long-term follow-up, including tests that detect changes in blood cell populations, vector integration patterns, and broader blood-related changes over time.

Immunogenicity Monitoring Across the Therapy Lifecycle

Immune monitoring works best as a lifecycle strategy, not a single check at one point in time. Baseline testing shows existing immunity to the vector’s shell, the therapeutic gene product, or engineered cell components. Sampling shortly after treatment captures early innate immune signals, cytokine changes, and complement activity. Sampling in the middle and later stages tracks adaptive immunity, including how antibodies mature, T cell responses, and how long the gene’s effect or the engineered cells last.

Human Plasma supports repeated measurement of anti-vector antibodies, complement activation markers, and soluble cytokines linked to infusion reactions or reduced effectiveness. Cellular immune tests commonly need PBMCs to check antigen-specific responses, changes in the immune cell mix, and activation or exhaustion patterns in engineered cell therapy. These immune patterns can directly affect whether re-dosing is possible in AAV programs, and how relapse happens in CAR-T programs.

Monitoring strategies should also account for the natural course of the underlying disease, especially in inherited disorders with ongoing tissue damage or inflammation that could muddy the immune signal. Thorough genomic annotation helps by allowing researchers to group patients by disease subtype, age, prior exposures, and relevant baseline inflammation.

Critical Quality Attributes for Gene Therapy Manufacturing

• Starting material cell counts, viability, and cell type mix that match the target product’s needs
• Infectious disease screening and sterility standards matched to the manufacturing stage and regulatory needs
• Activation and expansion benchmarks (growth rate, phenotype stability, exhaustion markers)
• Gene transfer or editing efficiency targets tied to potency and dosing feasibility
• Vector copy number or editing rate limits tied to efficacy and safety
• Reproducible potency assays that correlate with real functional results (cell killing, cytokines, growth)
• Freezing and thawing performance, including how well function is preserved after thaw

Key Considerations for Viral Vector Immunogenicity Studies

• Baseline anti-vector-shell antibody status measured in plasma, including neutralizing and binding antibody tests
• Complement activation and innate immune markers checked early after dosing, to catch risk signals
• Sampling plan designed to track antibody changes, class switching, and how long they persist
• Cellular immune monitoring using PBMC-based tests to detect T cell responses against the vector shell or therapeutic gene
• Grouping patients by age, prior viral exposure, and relevant clinical traits
• Standardized assays and reference controls so results are comparable across studies
• Checking how immune-suppressing drugs affect immune test results and how easy they are to interpret
• Considering whether re-dosing is feasible, based on how long neutralizing antibody responses last

Sanguine Bio: Biospecimen Support for Gene and Cell Therapy Development

Gene and cell therapy programs need specialized biospecimens matched to each stage of development — from discovery and assay development to GMP manufacturing and clinical monitoring. Sanguine Bio supports this work across the United States through a direct-to-donor model and an expanded donor network. This gives access to diverse healthy donors and disease-specific groups relevant to genetic disease and cell therapy programs.

Custom collection services allow protocol-specific sourcing for leukapheresis products, immune monitoring samples, and longitudinal sampling schedules that capture immune response and drug activity trends. From study design to receipt of samples, we support standardized processing workflows and thorough genomic annotation that improve interpretability and reduce variability before analysis.

Access to hard-to-find populations includes donors and patients suited for vector immune-response studies, rare genetic disease groups relevant to targeted gene therapy programs, and cellular starting material sources matched to specialized engineering workflows. These capabilities support both platform-level development and program-specific translational work.

Genetic Disease Biospecimens gives you one place to explore biospecimen solutions that support gene and cell therapy development programs.

Check Our Inventory to explore gene and cell therapy biospecimen solutions.

References

1. High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455-464.
2. Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351-360.
3. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23-36.
4. George LA, et al. Hemophilia gene therapy and immune considerations. N Engl J Med. 2017;377(26):2519-2530.
5. Coleman MA, et al. Complement activation in AAV gene therapy: mechanisms and mitigation. Mol Ther. 2021;29(12):1-12.
6. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388-398.
7. Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
8. Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell ALL. N Engl J Med. 2018;378(5):439-448.
9. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
10. Anzalone AV, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149-157.
11. Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. 2018;19(12):770-788.
12. Hacein-Bey-Abina S, et al. LMO2-associated clonal T cell proliferation in gene therapy. Science. 2003;302(5644):415-419.